Can a common arthritis drug ease MPS pain? new trial seeks answers.

NCT ID NCT03153319

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether adalimumab, a drug used for arthritis, can reduce pain and improve joint movement in people with MPS I, II, or VI. It includes children and adults aged 5 and older who have significant pain and limited joint motion. Participants receive either adalimumab or a placebo for 16 weeks, then all may receive the drug for up to a year. The goal is to see if the drug improves daily life and physical function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUCOPOLYSACCHARIDOSIS II are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Mucopolysaccharidosis I mucopolysaccharidosis type 1 mucopolysaccharidosis type 2 mucopolysaccharidosis type 6

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Lundquist Institute at Harbor-UCLA Medical Center

    Torrance, California, 90502, United States